Kura Oncology’s (KURA) “Market Outperform” Rating Reiterated at Citizens Jmp

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reissued by stock analysts at Citizens Jmp in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $24.00 price objective on the stock. Citizens Jmp’s target price would suggest a potential upside of 101.85% from the stock’s previous close.

A number of other analysts have also issued reports on KURA. CLSA set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Wedbush lifted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Finally, Oppenheimer set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $25.40.

Kura Oncology Stock Performance

Shares of KURA stock opened at $11.89 on Monday. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -3.53 and a beta of 0.38. Kura Oncology has a 1-year low of $7.36 and a 1-year high of $12.90. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. The stock’s fifty day simple moving average is $10.53 and its 200-day simple moving average is $9.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The firm had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. On average, sell-side analysts predict that Kura Oncology will post -3.23 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider directly owned 195,444 shares of the company’s stock, valued at $2,468,457.72. This represents a 13.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Troy Edward Wilson purchased 100,000 shares of Kura Oncology stock in a transaction on Monday, August 17th. The stock was bought at an average cost of $11.12 per share, with a total value of $1,112,000.00. Following the transaction, the chief executive officer directly owned 379,194 shares of the company’s stock, valued at approximately $4,216,637.28. The trade was a 35.82% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 7.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KURA. Dimensional Fund Advisors LP lifted its holdings in Kura Oncology by 32.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after purchasing an additional 348,127 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Kura Oncology by 69.7% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after buying an additional 233,633 shares during the period. UBS Group AG grew its stake in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares during the last quarter. Nan Fung Trinity HK Ltd. lifted its position in Kura Oncology by 317.9% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after acquiring an additional 734,000 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its holdings in Kura Oncology by 285.6% during the first quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock valued at $1,291,000 after acquiring an additional 117,650 shares during the period.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.